Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Josip Grah is active.

Publication


Featured researches published by Josip Grah.


Tumori | 2014

Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer

Josip Grah; Darko Katalinic; Antonio Juretić; Fedor Santek; Miroslav Samarzija

Aims and Background This paper deals with the clinical significance of the immunohistochemical expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 antigens in patients with non-small cell lung cancer (NSCLC). Methods and Study Design The study included 80 patients with NSCLC (40 with adenocarcinoma, 40 with squamous cell carcinoma) who had undergone surgery. MAGEA1 and MAGE-A3/4 antigen expression was determined by an immunohistochemical method using the monoclonal antibody 57B, and NY-ESO-1 antigen expression was determined with the addition of the B9.8.1.1 antibody. The expression of these antigens was compared with the clinicopathological features of the tumors and the survival of the patients. Results MAGE-A1, MAGE-A3/4 and NY-ESO-1 were expressed in 17.3%, 44.4% and 18.5% of NSCLC patients, respectively. A statistically higher immunohistological expression rate of MAGE-A3/4 was found in squamous cell carcinoma (P <0.001) and a significantly higher amount of tumor necrosis was observed in tumors with MAGE-3 expression (P= 0.001), but no correlation with positive lymph nodes was found. There was a statistically significant correlation between MAGE-A1 expression in adenocarcinoma and the presence of tumor necrosis (P = 0.05). Furthermore, there was a significant correlation between NY-ESO-1 expression and positive lymph nodes in adenocarcinoma, but not in squamous cell carcinoma. No statistically significant difference in patient survival was found with regard to tumor type and the observed histopathological characteristics except tumor size. Statistically significantly better survival was found in the group of patients with adenocarcinomas who had positive expression of MAGE-A3/4 (P = 0.012). Conclusions This study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC.


World Journal of Surgical Oncology | 2013

Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy

Josip Grah; Darko Katalinic; Ranka Štern-Padovan; Josip Paladino; Fedor Santek; Antonio Juretić; Kamelija Zarkovic; Stjepko Pleština; Marijana Supe

Despite huge advances in medicine, glioblastoma multiforme (GBM) remains a highly lethal, fast-growing tumour that cannot be cured by currently available therapies. However, extracranial and extraneural dissemination of GBM is extremely rare, but is being recognised in different imaging studies. To date, the cause of the GBM metastatic spread still remains under discussion. It probably develops at the time of intracranial progression following a surgical procedure. According to other hypothesis, the metastases are a consequence of spontaneous tumour transdural extension or haematogenous dissemination. We present a case of a 59-year-old woman with symptomatic leptomeningeal and intramedullary metastases of GBM who has been previously surgically treated with primary subtotal resection and underwent a repeated surgery during adjuvant radiotherapy and chemotherapy with temozolomide. Today, the main goal of surgery and chemoradiotherapy is to prevent neurologic deterioration and improve health-related quality of life. With this paper, we want to present this rare entity and emphasise the importance of a multidisciplinary approach, a key function in the management of brain tumour patients. The prognosis is still very poor although prolongation of survival can be obtained. Finally, although rare, our case strongly suggests that clinicians should be familiar with the possibility of the extracranial spread of GBM because as treatment improvements provide better control of the primary tumour and improving survival, metastatic disease will be increasingly encountered.


Arhiv Za Higijenu Rada I Toksikologiju | 2016

Age and sex differences in genome damage between prepubertal and adult mice after exposure to ionising radiation

Ranko Stojković; Aleksandra Fučić; Dušica Ivanković; Zoran Jukić; Petra Radulović; Josip Grah; Nenad Kovačević; Lovro Barišić; Božo Krušlin

Abstract The mechanisms that lead to sex and age differences in biological responses to exposure to ionising radiation and related health risks have still not been investigated to a satisfactory extent. The significance of sex hormones in the aetiology of radiogenic cancer types requires a better understanding of the mechanisms involved, especially during organism development. The aim of this study was to show age and sex differences in genome damage between prepubertal and adult mice after single exposure to gamma radiation. Genome damage was measured 24 h, 48 h, and 72 h after exposure of 3-week and 12-week old BALB/CJ mice to 8 Gy of gamma radiation using an in vivo micronucleus assay. There was a significantly higher genome damage in prepubertal than in adult animals of both sexes for all sampling times. Irradiation caused a higher frequency of micronuclei in males of both age groups. Our study confirms sex differences in the susceptibility to effects of ionising radiation in mice and is the first to show that such a difference occurs already at prepubertal age.


Collegium Antropologicum | 2008

Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer : the relationship with clinical-pathological features.

Josip Grah; Mirko Šamija; Antonio Juretić; Božena Šarčević; Hrvoje Šobat


Anticancer Research | 2016

Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease

Jasna Radić; Božo Krušlin; Mirko Šamija; Monika Ulamec; Milan Milošević; Marijana Jazvić; Ivan Šamija; Josip Grah; Ante Bolanča; Zvonko Kusić


Ejc Supplements | 2017

Immunohistochemical expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 antigens in patients with non-small cell lung cancer: Is there any impact on the specific immuntherapy?

Darko Katalinic; Josip Grah


16th European Congress of Endocrinology | 2014

Ca 19-9: Is there a role for potential new biomarker for medullary thyroid cancer?

Darko Katalinic; Fedor Šantek; Antonio Juretić; Ranka Štern-Padovan; Nora Nikolac; Josip Grah; Stjepko Plestina


Urološki simpozij : knjiga sazetaka / | 2013

Imunoterapija uroloskih tumora

Antonio Juretić; Katarina Pućo; Vesna Bišof; Darko Katalinic; Zoran Rakušić; Fedor Šantek; Josip Grah


Paediatria Croatica | 2013

ZLOĆUDNI GLIOMI I ULOGA CITOSTATIKA TEMOZOLOMIDA U NJIHOVOM LIJEČENJU

Ana Mišir Krpan; Antonio Juretić; Fedor Šantek; Lea Galunić Bilić; Zoran Rakušić; Josip Grah; Tonko Herceg; Zdenko Krajina; Kresimir Loncar; Martina Bašić Koretić


Archive | 2013

Dijagnostika i liječenje limfoma - drugi hrvatski konsenzus Lymphoma diagnosis and treatment - second Croatian consensus]

Igor Aurer; Slavko Gašparov; Marko Kralik; Antonija Balenović; Dražen Huić; Fedor Šantek; Antica Duletić-Načinović; Vlatko Pejša; Slobodanka Ostojić-Kolonić; Josip Grah

Collaboration


Dive into the Josip Grah's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fedor Šantek

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dražen Huić

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Igor Aurer

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge